182 related articles for article (PubMed ID: 21735097)
1. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Kyshenia YV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Ostrynska OV; Yarmoluk SM
Mol Cell Biochem; 2011 Oct; 356(1-2):107-15. PubMed ID: 21735097
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
3. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
5. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
Patel S; Vyas VK; Sharma M; Ghate M
Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
Schnitzler A; Niefind K
Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
[TBL] [Abstract][Full Text] [Related]
8. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
10. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
Wang X; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
[TBL] [Abstract][Full Text] [Related]
11. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
12. Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
[TBL] [Abstract][Full Text] [Related]
13. Expanding the chemical diversity of CK2 inhibitors.
Prudent R; Moucadel V; López-Ramos M; Aci S; Laudet B; Mouawad L; Barette C; Einhorn J; Einhorn C; Denis JN; Bisson G; Schmidt F; Roy S; Lafanechere L; Florent JC; Cochet C
Mol Cell Biochem; 2008 Sep; 316(1-2):71-85. PubMed ID: 18563535
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.
Gratz A; Kuckländer U; Bollig R; Götz C; Jose J
Mol Cell Biochem; 2011 Oct; 356(1-2):83-90. PubMed ID: 21750981
[TBL] [Abstract][Full Text] [Related]
15. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
Ostrynska OV; Balanda AO; Bdzhola VG; Golub AG; Kotey IM; Kukharenko OP; Gryshchenko AA; Briukhovetska NV; Yarmoluk SM
Eur J Med Chem; 2016 Jun; 115():148-60. PubMed ID: 27017545
[TBL] [Abstract][Full Text] [Related]
17. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
18. Interactions between subunits of protein kinase CK2 and their protein substrates influences its sensitivity to specific inhibitors.
Janeczko M; Masłyk M; Szyszka R; Baier A
Mol Cell Biochem; 2011 Oct; 356(1-2):121-6. PubMed ID: 21755460
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors.
Oramas-Royo S; Haidar S; Amesty Á; Martín-Acosta P; Feresin G; Tapia A; Aichele D; Jose J; Estévez-Braun A
Bioorg Chem; 2020 Jan; 95():103520. PubMed ID: 31887475
[TBL] [Abstract][Full Text] [Related]
20. A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
De Fusco C; Brear P; Iegre J; Georgiou KH; Sore HF; Hyvönen M; Spring DR
Bioorg Med Chem; 2017 Jul; 25(13):3471-3482. PubMed ID: 28495381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]